GlaxoSmithKline Pharmaceuticals Limited (GSK) Delivers Strong Q3 Performance with Double-Digit Growth
Mumbai, India - GlaxoSmithKline Pharmaceuticals Ltd (GSK) announced its financial results for the third quarter ended December 31, 2024, demonstrating strong growth and sustained profitability. The company reported a 18% increase in revenue from operations, reaching INR 946 crores while achieving a Profit After Tax (PAT) of INR 229 crores.
The quarter saw strong performance across key product portfolios. Flagship brands within the general medicines portfolio including Augmentin, Ceftum, and T-bact strengthened their market positions with share gains. The company's innovative Respiratory portfolio, led by Nucala and Trelegy, achieved robust growth, further expanding patient access across India.
In the vaccines segment, GSK maintained its leadership in the self-pay private market for Paediatric vaccines. The adult vaccines division continues to gain momentum with Shingrix (Herpes Zoster Vaccine – recombinant, adjuvanted), as the company spearheads the expansion of adult immunisation in India.
Commenting on the results, Mr. Bhushan Akshikar, Managing Director, GlaxoSmithKline Pharmaceuticals Limited, said, "Our strong third-quarter results reflect our unwavering commitment to deliver innovative healthcare solutions to patients across India. By focusing on core brands and accelerating digital transformation through innovative go to-market strategies, we continue to strengthen our market presence while ensuring broader access to our medicines and vaccines."
About GlaxoSmithKline Pharmaceuticals Limited: GlaxoSmithKline Pharmaceuticals Limited is a subsidiary of GSK plc, a science-led global healthcare company with a purpose to unite science, technology, and talent to get ahead of disease together. For more information, visit GSK-India.com.
Media Contact
Ransom D'Souza - ransom.a.dsouza@gsk.com
Communications & Government Affairs
